Next Article in Journal
Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues
Next Article in Special Issue
Involvement of E3 Ligases and Deubiquitinases in the Control of HIF-α Subunit Abundance
Previous Article in Journal
Evolutionary Divergence of Duplicated Hsf Genes in Populus
Previous Article in Special Issue
Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?
Open AccessArticle

2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α

Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, China
Guangzhou First People’s Hospital, School of Medicine and Institutes for Life Sciences, South China University of Technology, Guangzhou 510006, China
Third Institute of Oceanography, Ministry of Natural Resources, Xiamen 361005, China
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Cells 2019, 8(5), 439;
Received: 23 March 2019 / Revised: 27 April 2019 / Accepted: 2 May 2019 / Published: 10 May 2019
(This article belongs to the Special Issue Gene Regulation by HIFs during Hypoxia)
HIF-1 serves as an important regulator in cell response to hypoxia. Due to its key role in promoting tumor survival and progression under hypoxia, HIF-1 has become a promising target of cancer therapy. Thus far, several HIF-1 inhibitors have been identified, most of which are from synthesized chemical compounds. Here, we report that ALM (ActinoLactoMycin), a compound extracted from metabolites of Streptomyces flavoretus, exhibits inhibitory effect on HIF-1α. Mechanistically, we found that ALM inhibited the translation of HIF-1α protein by suppressing mTOR signaling activity. Treatment with ALM induced cell apoptosis and growth inhibition of cancer cells both in vitro and in vivo in a HIF-1 dependent manner. More interestingly, low dose of ALM treatment enhanced the anti-tumor effect of Everolimus, an inhibitor of mTOR, suggesting its potential use in combination therapy of tumors, especially solid tumor patients. Thus, we identified a novel HIF-1α inhibitor from the metabolites of Streptomyces flavoretus, which shows promising anti-cancer potential. View Full-Text
Keywords: ALM; hypoxia; HIF-1α; inhibitor; mTOR; combination therapy ALM; hypoxia; HIF-1α; inhibitor; mTOR; combination therapy
Show Figures

Figure 1

MDPI and ACS Style

Cheng, J.; Hu, L.; Yang, Z.; Suo, C.; Wang, Y.J.; Gao, P.; Cui, C.; Sun, L. 2-Oxonanonoidal Antibiotic Actinolactomycin Inhibits Cancer Progression by Suppressing HIF-1α. Cells 2019, 8, 439.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop